Kurepa Jasmina, Bruce Kristen A, Gerhardt Greg A, Smalle Jan A
Department of Plant and Soil Sciences, Martin-Gatton College of Agriculture Food and Environment, Kentucky Tobacco Research & Development Center, University of Kentucky, Lexington, KY 40546, USA.
Naprogenix, Inc., UK-AsTeCC, 145 Graham Avenue, Lexington, KY 40506, USA.
Appl Biosci (Basel). 2024 Jun;3(2):233-249. doi: 10.3390/applbiosci3020016. Epub 2024 May 20.
Synucleinopathies, typified by Parkinson's disease (PD), entail the accumulation of -synuclein (Syn) aggregates in nerve cells. Various Syn mutants, including the Syn A53T variant linked to early-onset PD, increase the propensity for Syn aggregate formation. In addition to disrupting protein homeostasis and inducing proteostatic stress, the aggregation of Syn in PD is associated with an imbalance in iron metabolism, which increases the generation of reactive oxygen species and causes oxidative stress. This study explored the impact of Syn A53T expression in transgenic hairy roots of four medicinal plants (, , , and ). In all tested plants, Syn A53T expression triggered proteotoxic stress and perturbed iron homeostasis, mirroring the molecular profile observed in human and animal nerve cells. In addition to the common eukaryotic defense mechanisms against proteostatic and oxidative stresses, a plant stress response generally includes the biosynthesis of a diverse set of protective secondary metabolites. Therefore, the hairy root cultures expressing Syn A53T offer a platform for identifying secondary metabolites that can ameliorate the effects of Syn, thereby aiding in the development of possible PD treatments and/or treatments of synucleinopathies.
以帕金森病(PD)为代表的突触核蛋白病,涉及α-突触核蛋白(Syn)聚集体在神经细胞中的积累。各种Syn突变体,包括与早发性PD相关的Syn A53T变体,增加了Syn聚集体形成的倾向。除了破坏蛋白质稳态并诱导蛋白稳态应激外,PD中Syn的聚集还与铁代谢失衡有关,这会增加活性氧的产生并导致氧化应激。本研究探讨了Syn A53T在四种药用植物(、、和)的转基因毛状根中的表达影响。在所有测试植物中,Syn A53T表达引发了蛋白毒性应激并扰乱了铁稳态,反映了在人类和动物神经细胞中观察到的分子特征。除了针对蛋白稳态和氧化应激的常见真核防御机制外,植物应激反应通常还包括多种保护性次生代谢物的生物合成。因此,表达Syn A53T的毛状根培养物为鉴定可改善Syn作用的次生代谢物提供了一个平台,从而有助于开发可能的PD治疗方法和/或突触核蛋白病的治疗方法。